Oncology data, organized for the people who need it most

I. The diagnosis

A diagnosis of cancer, at the level of the hospital system that issues it, is an information event. Notes are entered. Tests are scheduled. Specialists are consulted. Documents move between systems that were not designed to talk to one another. A patient with a suspicious finding, in the median U.S. health system, waits longer than they should for the next step — not because the medicine is slow but because the data is.

Azra AI, the Nashville-based oncology data platform, was built to compress that interval. The company’s software ingests the imaging, pathology, and clinical narrative produced by a hospital’s existing systems, identifies the patients whose findings warrant follow-up, and routes them — with the supporting context — to the navigators and specialists responsible for moving them forward.

II. The platform

Abinav Sankar, a managing partner of the Growth strategy, serves as Chairman. The firm’s involvement has tracked the company through multiple stages of growth, and the platform is now in use across a meaningful share of community oncology programs in the United States.

III. The category

What is striking about the category, from an investor’s vantage, is how unevenly the benefits of digitization have arrived in oncology. The genomic and imaging layers have advanced quickly. The orchestration layer — the software that turns a finding into a phone call — has not. Azra AI is building the orchestration layer.

That work is procedural, unglamorous, and consequential, which is the kind of company the firm has, over twenty years, been at its best in backing.